AMNEAL PHARMACEUTICALS, INC. $AMRX Shares Bought by Dark Forest Capital Management LP

Key Points

• Dark Forest Capital Management LP significantly increased its stake in Amneal Pharmaceuticals by 3,256.2%, acquiring 499,707 shares valued at approximately $4.19 million.
• Institutional investors collectively own 31.82% of Amneal Pharmaceuticals, with notable increases in holdings by Vanguard Group and Invesco during the first quarter.
• Amneal Pharmaceuticals reported earnings of $0.23 per share, exceeding analysts' expectations, and set a full-year 2025 guidance of 0.700-0.750 EPS.

Dark Forest Capital Management LP increased its holdings in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) by 3,256.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 499,707 shares of the company's stock after acquiring an additional 484,818 shares during the quarter. Dark Forest Capital Management LP owned approximately 0.16% of AMNEAL PHARMACEUTICALS worth $4,188,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of AMNEAL PHARMACEUTICALS by 6.2% in the first quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company's stock worth $132,092,000 after acquiring an additional 920,758 shares in the last quarter. Nantahala Capital Management LLC raised its stake in AMNEAL PHARMACEUTICALS by 3.9% during the first quarter. Nantahala Capital Management LLC now owns 3,808,561 shares of the company's stock valued at $31,916,000 after buying an additional 143,032 shares in the last quarter. BlackBarn Capital Partners LP raised its stake in AMNEAL PHARMACEUTICALS by 1.1% during the first quarter. BlackBarn Capital Partners LP now owns 2,881,654 shares of the company's stock valued at $24,148,000 after buying an additional 31,654 shares in the last quarter. Nuveen LLC acquired a new stake in AMNEAL PHARMACEUTICALS during the first quarter valued at approximately $19,581,000. Finally, Invesco Ltd. raised its position in shares of AMNEAL PHARMACEUTICALS by 19.2% during the 1st quarter. Invesco Ltd. now owns 2,272,713 shares of the company's stock worth $19,045,000 after purchasing an additional 365,467 shares during the period. Institutional investors and hedge funds own 31.82% of the company's stock.

Insider Transactions at AMNEAL PHARMACEUTICALS

In other AMNEAL PHARMACEUTICALS news, EVP Nikita Shah sold 114,492 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $9.66, for a total transaction of $1,105,992.72. Following the completion of the transaction, the executive vice president directly owned 152,743 shares of the company's stock, valued at approximately $1,475,497.38. This trade represents a 42.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John Kiely sold 32,000 shares of the stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $9.23, for a total value of $295,360.00. Following the transaction, the director directly owned 225,433 shares of the company's stock, valued at approximately $2,080,746.59. The trade was a 12.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 609,206 shares of company stock valued at $5,700,625. Company insiders own 17.45% of the company's stock.

Analysts Set New Price Targets

AMRX has been the topic of a number of research reports. Wall Street Zen cut AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. The Goldman Sachs Group initiated coverage on AMNEAL PHARMACEUTICALS in a research report on Friday, June 6th. They set a "buy" rating and a $12.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $11.60.

AMNEAL PHARMACEUTICALS Price Performance

AMRX stock traded up $0.07 on Monday, reaching $9.69. The company's stock had a trading volume of 385,997 shares, compared to its average volume of 1,664,851. The firm has a fifty day moving average of $8.67 and a two-hundred day moving average of $8.13. The company has a market capitalization of $3.04 billion, a P/E ratio of 969.47 and a beta of 1.19. AMNEAL PHARMACEUTICALS, INC. has a 52 week low of $6.68 and a 52 week high of $9.80.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a negative return on equity of 189.49% and a net margin of 0.12%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, equities analysts expect that AMNEAL PHARMACEUTICALS, INC. will post 0.53 EPS for the current fiscal year.

About AMNEAL PHARMACEUTICALS

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.